ACH 4471

Drug Profile

ACH 4471

Alternative Names: ACH-0144471; ACH-4471

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Haemolytic uraemic syndrome

Most Recent Events

  • 21 Mar 2017 Achillion Pharmaceuticals has patents pending for ACH 4471 in USA
  • 21 Mar 2017 Achillion Pharmaceuticals has patent protection for ACH 4471 in USA
  • 21 Mar 2017 USPTO issues Notices of Allowance for four patent applications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top